Cette étude analyse l'intérêt de prendre en compte les symptômes et la qualité de vie auto-déclarés par les patients âgés de 8 à 18 ans, atteints de cancer et inclus dans des essais cliniques de phase I ou II, comme critères de jugement

Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint?

Hinds, Pamela S. ; Wang, Jichuan ; Stern, Emily Dunn ; Macpherson, Catherine Fiona ; Wharton, Claire M. ; Okorosobo, Ruthanna ; Cheng, Yao Iris ; Gross, Heather E. ; Meany, Holly J. ; Jacobs, Shana

BACKGROUND: Pediatric participants on phase 1 or phase 2 clinical trials for incurable cancer are at risk of experiencing toxicities (adverse events [AEs]) related to trial participation. Multiple AEs are subjective; thus, the real impact of trial treatment cannot be known unless patient subjective reports are solicited. METHODS: The authors assessed the feasibility and acceptability of soliciting symptom, function, and quality of life (QOL) reports from participants aged 8 to 18 years who were [...]

A partir d'une revue systématique de la littérature et d'une enquête menée auprès de 32 médecins, infirmiers et patients atteints de cancer, cette étude analyse les différentes stratégies de prise en charge d'une neuropathie périphérique induite par la chimiothérapie

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey

McCrary, J. .. Matt ; Goldstein, David ; Boyle, Frances ; Cox, Keith ; Grimison, Peter ; Kiernan, Matthew C. ; Krishnan, Arun V. ; Lewis, Craig R. ; Webber, Kate ; Baron-Hay, Sally ; Horvath, Lisa ; Park, Susanna B.

Background/purpose : Chemotherapy-induced peripheral neuropathy (CIPN) is a prominent side effect of the treatment of cancer. Despite this frequent complication, there has been no comprehensive review and quality appraisal of CIPN assessments. The purpose of this study is to provide a definitive quality appraisal of CIPN assessment strategies for clinical use. Methods : Relevant studies were identified through database searches of Medline, Embase, CINAHL, and Cochrane. CIPN assessment [...]

Menée à partir des données du registre californien des cancers portant sur 20 221 patients atteints d'un carcinome hépatocellulaire disgnostiqué entre 2000 et 2009, cette étude évalue l'association entre une exposition à des particules fines et la mortalité spécifique

Particulate matter air pollution and liver cancer survival

Deng, Huiyu ; Eckel, Sandrah P. ; Liu, Lihua ; Lurmann, Frederick W. ; Cockburn, Myles G. ; Gilliland, Frank D.

Particulate matter (PM) air pollution exposure has been associated with cancer incidence and mortality especially with lung cancer. The liver is another organ possibly affected by PM due to its role in detoxifying xenobiotics absorbed from PM. Various studies have investigated the mechanistic pathways between inhaled pollutants and liver damage, cancer incidence, and tumor progression. However, little is known about the effects of PM on liver cancer survival. Twenty thousand, two hundred and [...]

Menée en France à partir des donnés de 19 registres des cancers sur la période 1989-2013, cette étude analyse l'évolution de la survie chez des patients atteints de 35 types de tumeurs solides

Survival of solid cancer patients in France, 1989-2013: a population-based study

Cowppli-Bony, Anne ; Uhry, Zoé ; Remontet, Laurent ; Voirin, Nicolas ; Guizard, Anne-Valérie ; Tretarre, Brigitte ; Bouvier, Anne-Marie ; Colonna, Marc ; Bossard, Nadine ; Woronoff, Anne-Sophie ; Grosclaude, Pascale ; French Network of Cancer Registries

This study provides updates of net survival (NS) estimates at 5, 10, and 15 years as well as survival trends for 35 solid cancers in France using data from 19 population-based cancer registries. The study considered all cases of solid cancer diagnosed between 1989 and 2010 in patients older than 15 years of age who were actively followed up until 30 June 2013. NS was estimated using the Pohar-Perme method. The age-standardized NS used the international cancer survival standard weights. The [...]

A partir des données GLOBOCAN 2012, cette étude évalue la part des cancers attribuables à une infection par le papillomavirus humain (HPV) au niveau mondial, et analyse les disparités géographiques dans l'incidence des cancers liés au HPV, par localisation cancéreuse et par sous-type de HPV

Worldwide burden of cancer attributable to HPV by site, country and HPV type

de Martel, Catherine ; Plummer, Martyn ; Vignat, Jérôme ; Franceschi, Silvia

HPV is the cause of almost all cervical cancer and is responsible for a substantial fraction of other anogenital cancers and oropharyngeal cancers. Understanding the HPV-attributable cancer burden can boost programs of HPV vaccination and HPV-based cervical screening. Attributable fractions (AFs) and the relative contributions of different HPV types were derived from published studies reporting on the prevalence of transforming HPV infection in cancer tissue. Maps of age-standardized incidence [...]

Menée aux Etats-Unis à partir de données portant sur 1 184 patientes atteintes d'un cancer épithélial de l'ovaire diagnostiqué entre 2000 et 2013, cette étude de cohorte évalue l'association entre l'indice de masse corporelle et la survie, en fonction du stade de la maladie (durée médiane de suivi : 37 mois)

Impact of body mass index on ovarian cancer survival varies by stage

Bandera, Elisa V. ; Lee, Valerie S. ; Qin, Bo ; Rodriguez-Rodriguez, Lorna ; Powell, C. Bethan ; Kushi, Lawrence H.

Background: Research on the effect of body mass index (BMI) on ovarian cancer survival is inconsistent, but previous studies did not consider the possible impact of ascites, bowel obstruction, or cachexia, which commonly occur in late-stage disease. Methods: We evaluated the association of BMI, before and around the time of diagnosis, with overall and disease-specific survival in a cohort study of primary invasive epithelial ovarian cancers diagnosed from 2000 to 2013 in Kaiser Permanente [...]

Menée en France à partir de données portant sur la période 1982-2012, cette étude analyse l'évolution de l'incidence du cancer du pancréas et de la mortalité spécifique

Focus on an unusual rise in pancreatic cancer incidence in France

Anne-Marie Bouvier, ; Zoé Uhry, ; Valérie Jooste, ; Antoine Drouillard, ; Laurent Remontet, ; Guy Launoy, ; Nathalie Leone, ; the French Network of Cancer Registries (FRANCIM)

Background: Pancreatic cancer is one of the most lethal. Most countries have exhibited a stable or decreasing incidence over time. The aim of this study was to provide updated French temporal trends in pancreatic cancer incidence and mortality over the past three decades. Methods: Incidence was estimated using the French National Network of Cancer Registries (FRANCIM) and mortality using the French Mortality Statistics Office. World age-standardized incidence and mortality were modelled by [...]

A partir de données internationales portant sur la période 1978-2007, cette étude analyse l'évolution de l'incidence du cancer du rein dans 16 populations (âge : 30-74 ans) ainsi que les facteurs de risque associés

Less overdiagnosis of kidney cancer? an age-period-cohort analysis of incidence trends in 16 populations worldwide

Znaor, Ariana ; Laversanne, Mathieu ; Bray, Freddie

The increasing rates of kidney cancer incidence, reported in many populations globally, have been attributed both to increasing exposures to environmental risk factors, as well as increasing levels of incidental diagnosis due to widespread use of imaging. To better understand these trends, we examine long-term cancer registry data worldwide, focusing on the roles of birth cohort and calendar period, proxies for changes in risk factor prevalence and detection practice respectively. We used an [...]

Cette étude présente les recommandations de l''Association Francophone des Soins Oncologiques de Support" (AFSOS) et de la "Société Française de Psycho-Oncologie" (SFPO) pour la prise en charge des patients adultes atteints de cancer refusant d'être traités

Clinical practice guidelines of the French Association for Supportive Care in Cancer and the French Society for Psycho-oncology: refusal of treatment by adults afflicted with cancer

Faivre, J. C. ; Adam, V. ; Block, V. ; Metzger, M. ; Salleron, J. ; Dauchy, S.

Purpose : The study’s purpose was to develop practical guidelines for assessment and management of refusal of treatment by adults afflicted with cancer. Methods : The French Association for Supportive Care in Cancer and the French Society for Psycho-oncology gathered a task force that applied a consensus methodology to draft guidelines studied predisposing situations, the diagnosis, regulatory aspects, and the management of refusal of treatment by adults afflicted with cancer. Results : We [...]

A partir d'une revue systématique de la littérature (78 études), cette étude analyse l'efficacité de divers outils permettant d'évaluer les symptômes d'anxiété chez des enfants et adolescents atteints de cancer ou recevant une greffe de cellules souches hématopoïétiques

Instruments to measure anxiety in children, adolescents, and young adults with cancer: a systematic review

Lazor, Tanya ; Tigelaar, Leonie ; Pole, Jason D. ; De Souza, Claire ; Tomlinson, Deborah ; Sung, Lillian

Purpose : The primary objective was to describe anxiety measurement instruments used in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation (HSCT) and summarize their content and psychometric properties. Methods : We conducted searches of MEDLINE, Embase, PsycINFO, HAPI, and CINAHL. We included studies that used at least one instrument to measure anxiety quantitatively in children or adolescents with cancer or undergoing HSCT. Two authors independently [...]

Menée par questionnaire auprès de patients atteints d'un cancer de stade avancé, incurable et récemment diagnostiqué, cette étude évalue l'association entre leur connaisance du pronostic de la maladie, leur façon de faire face à la maladie, leurs troubles psychiques (dépression, anxiété) et leur qualité de vie

Coping and Prognostic Awareness in Patients With Advanced Cancer

Ryan D. Nipp ; Joseph A. Greer ; Areej El-Jawahri ; Samantha M. Moran ; Lara Traeger ; Jamie M. Jacobs ; Juliet C. Jacobsen ; Emily R. Gallagher ; Elyse R. Park ; David P. Ryan ; Vicki A. Jackson ; William F. Pirl ; Jennifer S. Temel

Purpose : Patients’ understanding of their illness is key for making informed treatment decisions, yet studies suggest an association between prognostic awareness and worse quality of life (QOL) and mood among patients with advanced cancer. We sought to explore the relationships among prognostic awareness, coping, QOL, and mood in patients with newly diagnosed, incurable cancer. Methods : We assessed patients’ self-reported health status and treatment goal (Prognosis and Treatment Perceptions [...]

Menée au Canada auprès de 56 patients atteints d'un carcinome épidermoïde de l'oropharynx lié à une infection par le papillomavirus humain et de 90 patient atteints d'un carcinome épidermoïde de la tête et du cou non oropharyngé, cette étude de cohorte rétrospective analyse, chez ces deux populations, les caractéristiques associées à leurs symptômes physiques et psychologiques (douleur, fatigue, anxiété, dépression)

Distress levels in patients with oropharyngeal vs. non-oropharyngeal squamous cell carcinomas of the head and neck over 1 year after diagnosis: a retrospective cohort study

Schorr, Melissa ; Carlson, Linda E. ; Lau, Harold Y. ; Zhong, Lihong ; Bultz, Barry D. ; Waller, Amy ; Groff, Shannon L. ; Hao, Desiree

Background : Human papillomavirus (HPV)-related cancers have been associated with different demographic profiles and disease characteristics than HPV-unrelated cancers in head and neck patients, but distress and other symptoms have not been compared. The aim of this study was to assess whether distress levels, fatigue, pain, anxiety, depression, and common psychological and practical problems differ between head and neck cancer patients with HPV-related vs. HPV-unrelated carcinomas (using [...]

A partir des données de 109 essais randomisés publiés entre 2011 et 2015 et incluant des patients atteints d'un cancer du poumon non à petites cellules, du sein, du côlon-rectum ou du pancréas, cette étude analyse le rapport coût-efficacité des traitements anticancéreux en comparant les méthodes proposées par l'"American Society of Clinical Oncology" et l'"European Society for Medical Oncology"

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks

Del Paggio, Joseph C. ; Sullivan, Richard ; Schrag, Deborah ; Hopman, Wilma M. ; Azariah, Biju ; Pramesh, C. S. ; Tannock, Ian F. ; Booth, Christopher M.

Background : The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that quantify survival gains in light of toxicity and quality of life to assess the benefits of cancer therapies. We applied these frameworks to a cohort of contemporary randomised controlled trials to explore agreement between the two approaches and to assess the relation between treatment benefit and cost. Methods : We identified all randomised [...]

A partir d'une revue systématique de la littérature (25 études), cette étude analyse les facteurs associés à la demande, par les patients atteints de cancer, d'un deuxième avis médical, puis évalue les effets de ce deuxième avis dans les diagnostics ou les traitements

Patient-Driven Second Opinions in Oncology: A Systematic Review

Hillen, Marij A. ; Medendorp, Niki M. ; Daams, Joost G. ; Smets, Ellen M. A.

Background : Although patient-driven second opinions are increasingly sought in oncology, the desirability of this trend remains unknown. Therefore, this systematic review assesses evidence on the motivation for and frequency of requests for second opinions and examines how they evolve and their consequences for oncological practice. Materials and Methods : Relevant databases were sought using the terms “cancer,” “second opinion,” and “self‐initiated.” Included were peer‐reviewed articles that [...]

A partir de données portant sur 12 361 patients atteints de cancer inclus dans des essais cliniques promus par un groupe coopérateur financé par le "National Cancer Institute" et ayant démontré l'efficacité d'un traitement (23 essais dits "positifs" entre 1965 et 2012), cette étude analyse le retour sur investissement associé à ces essais du point de vue des années de vie gagnées en population

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

Unger, J. M. ; LeBlanc, M. ; Blanke, C. D.

Importance : Recently, tremendous prominence has been given to the investigation of the effect of different research processes as part of the Cancer Moonshot. More than half a century ago, the National Cancer Institute (NCI) established a network of publicly funded cancer cooperative research groups to systematically evaluate new treatments for efficacy and safety. Objective : To examine the extent to which positive NCI-sponsored cancer treatment trials have benefited patients with cancer in [...]

Cette étude analyse le rapport coût-efficacité du bévacizumab pour traiter les patients atteints d'un cancer colorectal métastatique dans les contextes américain, britannique, canadien, australien et israëlien

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis

Goldstein, Daniel A. ; Chen, Qiushi ; Ayer, Turgay ; Chan, Kelvin K. W. ; Virik, Kiran ; Hammerman, Ariel ; Brenner, Baruch ; Flowers, Christopher R. ; Hall, Peter S.

Background : In the U.S., the addition of bevacizumab to first‐line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality‐adjusted life years (QALYs) at an incremental cost‐effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value for money may be different in other countries. Our objective was to establish the cost‐effectiveness of bevacizumab in mCRC in the U.S., U.K., Canada, Australia, and Israel. Methods : We performed the [...]

A partir d'une revue systématique de la littérature publiée entre 2005 et 2015 (98 articles), cette étude analyse l'utilisation des médias sociaux par les patientes ayant survécu à un cancer du sein et l'intérêt, notamment, des groupes de soutien en ligne et des forums de discussion pour améliorer le bien-être des patientes

Social media for breast cancer survivors: a literature review

Falisi, Angela L. ; Wiseman, Kara P. ; Gaysynsky, Anna ; Scheideler, Jennifer K. ; Ramin, Daniel A. ; Chou, Wen-ying Sylvia

Purpose : Social media may offer support to individuals who are navigating the complex and challenging experience of cancer. A growing body of literature has been published over the last decade exploring the ways cancer survivors utilize social media. This study aims to provide a systematic synthesis of the current literature in order to inform cancer health communication practice and cancer survivorship research. Methods : Using PRISMA guidelines, four electronic databases were searched to [...]

Menée aux Etats-Unis à partir de données portant sur 766 patients atteints d'une tumeur solide de stade métastatique et inclus dans un essai randomisé (âge médian : 61 ans), cet essai randomisé analyse, du point de vue de la survie globale, l'intérêt d'utiliser les données auto-déclarées en ligne par le patient afin d'améliorer la prise en charge de ses symptômes pendant les traitements

Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment

Basch, E. ; Deal, A. M. ; Dueck, A. C. ; et al.,

Symptoms are common among patients receiving treatment for advanced cancers, yet are undetected by clinicians up to half the time. There is growing interest in integrating electronic patient-reported outcomes (PROs) into routine oncology practice for symptom monitoring, but evidence demonstrating clinical benefit has been limited. We assessed overall survival associated with electronic patient-reported symptom monitoring vs usual care based on follow-up from a randomized clinical trial. Methods [...]